JP2019517541A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019517541A5 JP2019517541A5 JP2018563831A JP2018563831A JP2019517541A5 JP 2019517541 A5 JP2019517541 A5 JP 2019517541A5 JP 2018563831 A JP2018563831 A JP 2018563831A JP 2018563831 A JP2018563831 A JP 2018563831A JP 2019517541 A5 JP2019517541 A5 JP 2019517541A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- composition
- stabilizer
- microns
- cysteamine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 26
- 239000003381 stabilizer Substances 0.000 claims 6
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 claims 4
- 229960003151 mercaptamine Drugs 0.000 claims 4
- 239000002245 particle Substances 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- OOTFVKOQINZBBF-UHFFFAOYSA-N cystamine Chemical compound CCSSCCN OOTFVKOQINZBBF-UHFFFAOYSA-N 0.000 claims 3
- 229940099500 cystamine Drugs 0.000 claims 3
- 150000002148 esters Chemical class 0.000 claims 3
- 239000010419 fine particle Substances 0.000 claims 3
- 150000005846 sugar alcohols Chemical class 0.000 claims 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 2
- 208000019693 Lung disease Diseases 0.000 claims 2
- -1 hydrate Chemical class 0.000 claims 2
- 239000011859 microparticle Substances 0.000 claims 2
- 208000023504 respiratory system disease Diseases 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims 1
- 206010006458 Bronchitis chronic Diseases 0.000 claims 1
- 229940127291 Calcium channel antagonist Drugs 0.000 claims 1
- 206010011224 Cough Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 1
- 206010014561 Emphysema Diseases 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- 241000150452 Orthohantavirus Species 0.000 claims 1
- 206010035664 Pneumonia Diseases 0.000 claims 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 239000002220 antihypertensive agent Substances 0.000 claims 1
- 229940030600 antihypertensive agent Drugs 0.000 claims 1
- 239000004599 antimicrobial Substances 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 201000009267 bronchiectasis Diseases 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 229940124630 bronchodilator Drugs 0.000 claims 1
- 239000000168 bronchodilator agent Substances 0.000 claims 1
- 239000000480 calcium channel blocker Substances 0.000 claims 1
- 150000001720 carbohydrates Chemical class 0.000 claims 1
- 235000014633 carbohydrates Nutrition 0.000 claims 1
- 239000002327 cardiovascular agent Substances 0.000 claims 1
- 229940125692 cardiovascular agent Drugs 0.000 claims 1
- 208000007451 chronic bronchitis Diseases 0.000 claims 1
- 208000013116 chronic cough Diseases 0.000 claims 1
- 150000002016 disaccharides Chemical class 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003172 expectorant agent Substances 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 claims 1
- 206010022000 influenza Diseases 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 150000002772 monosaccharides Chemical group 0.000 claims 1
- 230000000510 mucolytic effect Effects 0.000 claims 1
- 229940066491 mucolytics Drugs 0.000 claims 1
- 229920001542 oligosaccharide Polymers 0.000 claims 1
- 150000002482 oligosaccharides Chemical class 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- 208000008423 pleurisy Diseases 0.000 claims 1
- 229920001282 polysaccharide Polymers 0.000 claims 1
- 239000005017 polysaccharide Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 239000007909 solid dosage form Substances 0.000 claims 1
- 229940095064 tartrate Drugs 0.000 claims 1
- 125000000647 trehalose group Chemical group 0.000 claims 1
- 150000004043 trisaccharides Chemical class 0.000 claims 1
- 229940124549 vasodilator Drugs 0.000 claims 1
- 239000003071 vasodilator agent Substances 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662346969P | 2016-06-07 | 2016-06-07 | |
| US62/346,969 | 2016-06-07 | ||
| GB1609940.0 | 2016-06-07 | ||
| GBGB1609940.0A GB201609940D0 (en) | 2016-06-07 | 2016-06-07 | Microparticles |
| PCT/GB2017/051637 WO2017212249A1 (en) | 2016-06-07 | 2017-06-06 | Microparticles comprising a sulphur-containing compound |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019517541A JP2019517541A (ja) | 2019-06-24 |
| JP2019517541A5 true JP2019517541A5 (enExample) | 2020-07-09 |
| JP7195934B2 JP7195934B2 (ja) | 2022-12-26 |
Family
ID=56508202
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018563831A Active JP7195934B2 (ja) | 2016-06-07 | 2017-06-06 | 硫黄含有化合物を含む微小粒子 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US11369568B2 (enExample) |
| EP (1) | EP3463325B1 (enExample) |
| JP (1) | JP7195934B2 (enExample) |
| KR (1) | KR102412212B1 (enExample) |
| CN (1) | CN109310654A (enExample) |
| AU (1) | AU2017277897B2 (enExample) |
| BR (1) | BR112018075221B1 (enExample) |
| CA (2) | CA3026743C (enExample) |
| DK (1) | DK3463325T3 (enExample) |
| ES (1) | ES2965017T3 (enExample) |
| FI (1) | FI3463325T3 (enExample) |
| GB (1) | GB201609940D0 (enExample) |
| MX (1) | MX2018014278A (enExample) |
| SG (1) | SG11201810934TA (enExample) |
| WO (1) | WO2017212249A1 (enExample) |
| ZA (1) | ZA201807852B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10905660B2 (en) | 2016-06-07 | 2021-02-02 | Novabiotics Limited | Microparticles |
| EP3572068A1 (en) * | 2018-05-22 | 2019-11-27 | RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.a. | New salt of cysteamine for the preparation of highly respirable particles |
| WO2020079186A1 (en) * | 2018-10-17 | 2020-04-23 | Novabiotics Limited | Dosage regime |
| JP2023540985A (ja) * | 2020-09-03 | 2023-09-27 | フィリップ・モーリス・プロダクツ・ソシエテ・アノニム | 噴霧乾燥低吸湿性活性粉末組成物 |
| US11793808B2 (en) | 2021-02-22 | 2023-10-24 | Mannkind Corp. | Compositions of clofazimine, combinations comprising them, processes for their preparation, uses and methods comprising them |
| CN118871100A (zh) * | 2021-12-07 | 2024-10-29 | 西拉治疗公司 | 抗病毒治疗剂及其用途 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE8901570D0 (sv) * | 1989-05-02 | 1989-05-02 | Draco Ab | Organic salts of cysteine derivatives |
| CN101094651B (zh) | 2004-12-30 | 2011-03-09 | 多贝尔有限公司 | 含有胶原凝集素家族蛋白质或者其变体的喷雾干燥的组合物和其制备方法 |
| AR057623A1 (es) | 2005-11-28 | 2007-12-05 | Omega Bio Pharma H K Ltd | Materiales y metodos para el tratamiento de las infecciones virales |
| JP5315252B2 (ja) | 2006-12-22 | 2013-10-16 | シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニ | 眼科用薬物の輸送に有用なゲル |
| CN101342155B (zh) * | 2007-07-11 | 2012-01-04 | 天津帝士力投资控股集团有限公司 | 一种(r,r)-福莫特罗吸入粉雾剂及其制备方法 |
| EP2370053A1 (de) * | 2008-11-27 | 2011-10-05 | Boehringer Ingelheim International GmbH | Neue pulverförmige kristalline arzneimittel zur inhalation |
| CN102341105B (zh) | 2009-02-03 | 2014-09-17 | 微生物公司 | 用作上皮组织、急性和慢性伤口、细菌生物被膜和其他适应症的抗菌剂的铋硫醇 |
| WO2010138419A2 (en) | 2009-05-23 | 2010-12-02 | Obio Pharmaceutical (H.K.) Ltd. | Materials and methods for treating viral infections |
| GB201021186D0 (en) * | 2010-12-14 | 2011-01-26 | Novabiotics Ltd | Composition |
| CN103717231B (zh) | 2011-05-19 | 2016-08-17 | 萨瓦拉股份有限公司 | 干粉万古霉素组合物以及相关方法 |
| JP5981123B2 (ja) | 2011-10-11 | 2016-08-31 | サンサ コーポレーション （バルバドス） インク | ニコチン薬の製造法およびその方法により製造される医薬 |
| US9468612B2 (en) * | 2011-10-26 | 2016-10-18 | Seattle Children's Hospital | Cysteamine in the treatment of fibrotic disease |
| US9493775B2 (en) * | 2012-02-10 | 2016-11-15 | Whitehead Institute For Biomedical Research | Inhibition of the glycine cleavage system for treatment of cancer |
| ITMI20130572A1 (it) * | 2013-04-10 | 2014-10-11 | Eratech Srl | Composizione comprendente almeno due polveri secche ottenute per spray dry per aumentare la stabilita' della formulazione |
| JP6483714B2 (ja) * | 2013-10-11 | 2019-03-13 | ローレンス エス． ジスマン， | 噴霧乾燥製剤 |
| GB201416716D0 (en) | 2014-09-22 | 2014-11-05 | Novabiotics Ltd | Use |
| ITUA20161799A1 (it) * | 2016-03-18 | 2017-09-18 | Recordati Ind Chimica E Farmaceutica S P A | Composizione farmaceutica a rilascio prolungato comprendente cisteamina o un suo sale |
| US10905660B2 (en) * | 2016-06-07 | 2021-02-02 | Novabiotics Limited | Microparticles |
-
2016
- 2016-06-07 GB GBGB1609940.0A patent/GB201609940D0/en not_active Ceased
-
2017
- 2017-06-06 FI FIEP17735616.9T patent/FI3463325T3/fi active
- 2017-06-06 DK DK17735616.9T patent/DK3463325T3/da active
- 2017-06-06 US US16/307,990 patent/US11369568B2/en active Active
- 2017-06-06 MX MX2018014278A patent/MX2018014278A/es unknown
- 2017-06-06 CN CN201780035360.7A patent/CN109310654A/zh active Pending
- 2017-06-06 JP JP2018563831A patent/JP7195934B2/ja active Active
- 2017-06-06 SG SG11201810934TA patent/SG11201810934TA/en unknown
- 2017-06-06 AU AU2017277897A patent/AU2017277897B2/en active Active
- 2017-06-06 CA CA3026743A patent/CA3026743C/en active Active
- 2017-06-06 ES ES17735616T patent/ES2965017T3/es active Active
- 2017-06-06 CA CA3096121A patent/CA3096121C/en active Active
- 2017-06-06 WO PCT/GB2017/051637 patent/WO2017212249A1/en not_active Ceased
- 2017-06-06 EP EP17735616.9A patent/EP3463325B1/en active Active
- 2017-06-06 BR BR112018075221-5A patent/BR112018075221B1/pt active IP Right Grant
- 2017-06-06 KR KR1020187035476A patent/KR102412212B1/ko active Active
-
2018
- 2018-11-21 ZA ZA2018/07852A patent/ZA201807852B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019517541A5 (enExample) | ||
| HRP20211035T1 (hr) | Tekuća formulacija za inhalaciju koja sadrži rpl554 | |
| UA107499C2 (uk) | Склад сухого порошку, який містить антимускариновий засіб | |
| JP2015509788A5 (enExample) | ||
| JP2007505830A5 (enExample) | ||
| FI3463325T3 (fi) | Mikrohiukkaset, jotka käsittävät rikkiä sisältävää yhdistettä | |
| JP2016534153A5 (enExample) | ||
| HRP20210749T1 (hr) | Farmaceutski pripravci koji sadrže azd9291 | |
| HRP20130052T1 (hr) | Lijeäśenje respiratorne bolesti | |
| JP2013536845A5 (enExample) | ||
| HRP20220919T3 (hr) | Sastav za inhalaciju koji sadrži aklidinij za liječenje kronične opstruktivne bolesti pluća | |
| JP2012176990A5 (enExample) | ||
| JP2016512494A5 (enExample) | ||
| IL273388B2 (en) | Preparations and methods for treating and improving respiratory conditions and mucosal inflammation | |
| JP2011520911A5 (enExample) | ||
| JP2012503668A5 (enExample) | ||
| SI2760821T1 (en) | A salt salt of an anti-inflammatory substituted cyclobutenedione compound | |
| JP2017528479A5 (enExample) | ||
| JP2016513625A5 (enExample) | ||
| JP2020513032A5 (enExample) | ||
| ECSP11010925A (es) | Partículas inhalables que comprenden tiotropio | |
| JP2015510916A5 (enExample) | ||
| JP2008518007A5 (enExample) | ||
| JP2018537453A5 (enExample) | ||
| MX2017004476A (es) | Composicion que comprende al menos un polvo seco obtenido por secado por atomizacion para aumentar la estabilidad de la formulacion. |